Pelage Pharmaceuticals, a Los Angeles-based clinical-stage biotechnology company developing regenerative treatments for hair loss, announced on October 14, 2026, that the first participant has been dosed in AWAKEN, its randomized Phase 2/3 clinical trial of PP405 for androgenetic alopecia. The study will enroll approximately 600 adult men across the United States and Canada, evaluating whether a topical small-molecule treatment can reactivate dormant hair follicle stem cells and increase measurable hair growth in patients with established male pattern hair loss.
The trial follows a positive end-of-Phase 2 meeting with the United States Food and Drug Administration and represents Pelage’s first late-stage clinical investigation of PP405. AWAKEN will include 24 weeks of randomized treatment followed by a longer safety assessment extending to Week 52. Its main efficacy endpoint will measure changes in non-vellus hair count, providing a quantitative assessment of whether the experimental formulation produces visible, substantive hair growth rather than changes limited to fine, immature hairs.
The programme builds on a 78-participant Phase 2a study that included men and women with androgenetic alopecia. Among men with more advanced hair loss, Pelage reported that 31% receiving PP405 achieved more than a 20% improvement in hair density at Week 8, compared with no responders in the corresponding vehicle-control group. However, the result came from an exploratory subgroup analysis rather than a successful prespecified pivotal efficacy endpoint, making confirmation in a larger trial essential.
Pelage is developing PP405 as a non-hormonal alternative to established treatments such as minoxidil and finasteride. The medicine aims to stimulate hair production through metabolic changes within dormant follicles rather than primarily altering androgen signaling. If AWAKEN demonstrates a reproducible benefit with acceptable long-term safety, the approach could introduce a different therapeutic mechanism into a market where many patients remain dissatisfied with available treatments.
How will the 600-patient AWAKEN trial measure PP405’s effectiveness?
AWAKEN, registered as NCT07819435, is a multicenter, double-blind, vehicle-controlled Phase 2/3 investigation involving men aged 18 to 55 years. Participants must have androgenetic alopecia corresponding to Norwood-Hamilton Type IV or V, representing established patterns of hair loss involving the frontal scalp, crown or both regions. The study is designed to establish whether PP405 produces clinically meaningful growth within an appropriate treatment population.
The trial will initially randomize participants in equal proportions to PP405 0.05% topical gel or a matching vehicle without the active drug. This controlled phase will continue for 24 weeks, allowing investigators to compare changes in hair growth while reducing the influence of expectations and other factors. The primary efficacy measure is the change from baseline in non-vellus target area hair count at the vertex of the scalp.
Non-vellus hairs are larger, more developed hairs rather than the fine, short hairs frequently associated with follicular miniaturization. Measuring their number within a defined scalp area provides an objective way to evaluate changes potentially relevant to visible hair density. The endpoint is more informative than relying exclusively on patient impressions or photographs without standardized measurement.
At Week 24, participants originally assigned to PP405 will continue active treatment. Those receiving vehicle will be randomized again to receive PP405 or remain on vehicle during the longer safety extension, with follow-up continuing through Week 52. This design will provide additional treatment exposure while preserving a controlled comparison for part of the extended observation period.
The registry currently identifies December 2027 as the estimated primary completion date and June 2028 as the expected overall study completion. These are planning dates rather than confirmed results or regulatory submission deadlines. The actual timeline will depend on enrollment, treatment completion, data quality and subsequent development decisions.
What did the earlier Phase 2a study establish about hair regrowth?
The Phase 2a study enrolled 78 adults with androgenetic alopecia, including men and women representing different skin phototypes and hair textures. Participants applied PP405 or a matching vehicle once daily for four weeks and were followed for approximately 12 weeks. Its primary objective concerned safety, with pharmacokinetics and exploratory hair-growth measurements providing additional information.
Pelage reported that the trial met its primary safety endpoint and that PP405 was generally well tolerated. The company also stated that drug concentrations were not detectable in participants’ blood under the study’s analytical testing conditions. That observation supports low measured systemic exposure during the short treatment period but does not establish that systemic absorption is biologically impossible under every dosing condition.
The most prominent efficacy finding involved men with a higher degree of hair loss. At Week 8, approximately four weeks after completing treatment, 31% of treated men in that subgroup achieved more than a 20% increase in hair density. No participants in the corresponding vehicle-control subgroup met the same response threshold.
The company also reported observations of new growth in scalp regions where measurable hair had not previously been present. These findings support its hypothesis that treatment can influence follicles with limited visible activity. However, they do not establish that entirely destroyed follicles can regenerate or that all longstanding bald areas retain sufficient biological capacity to respond.
Importantly, Pelage has not disclosed the complete subgroup denominator underlying the 31% result in its public announcement. The difference from placebo is encouraging, but its precision cannot be fully evaluated without the number of participants, confidence intervals and complete statistical analysis. AWAKEN is intended to provide stronger evidence under a larger, prospectively defined study design.
Why is PP405 targeting follicle metabolism rather than androgen signaling?
Androgenetic alopecia involves the progressive miniaturization of susceptible hair follicles, influenced by genetic factors and androgen-related signaling. As affected follicles become smaller, they produce progressively finer hairs and may spend increasing periods outside active growth. Over time, areas of the scalp can show substantial thinning even when some underlying follicular structures remain.
Pelage is investigating a different biological intervention centered on the metabolic state of hair follicle stem cells. These cells normally alternate between periods of dormancy and activation as part of the hair-growth cycle. Their ability to enter an active state is influenced by internal metabolic pathways as well as signals from the surrounding follicular environment.
Research published in Nature Cell Biology in 2017 showed that hair follicle stem cells use glycolytic metabolism and generate relatively high levels of lactate. Experimental disruption of lactate production impaired stem cell activation, while changes involving mitochondrial pyruvate carrier activity promoted activation and accelerated hair cycling in laboratory models. These findings helped establish a scientific rationale for pharmacologically modifying follicular metabolism.
PP405 is designed to influence this metabolic switch and support activation of dormant hair follicle stem cells. The company’s research programme is based on more than a decade of work examining the relationship between cellular metabolism and hair growth. However, mechanistic findings from experimental systems cannot establish that the same magnitude of follicular activation will occur in patients with advanced androgenetic alopecia.
The potential advantage is that the treatment does not rely on blocking a hormonal pathway. That could eventually make it relevant to different patient populations, including women, but suitability across sexes must be confirmed through the respective clinical programmes.
How does PP405 differ from minoxidil and finasteride?
Minoxidil and finasteride are among the most established treatments for androgenetic alopecia, although their approved uses and mechanisms differ. Topical minoxidil is used to promote hair growth in appropriate patients, while finasteride reduces conversion of testosterone into dihydrotestosterone, a hormone involved in androgen-sensitive follicle miniaturization. Neither produces the same response in every patient.
Minoxidil’s effects involve several biological pathways associated with follicle function and hair cycling. Finasteride intervenes more directly in androgen metabolism, making its use and risk considerations different from those of a topical non-hormonal medicine. Treatment selection depends on the patient’s age, sex, medical circumstances and the approved product information.
PP405’s proposed differentiation involves the activation of dormant stem cells through cellular metabolism. It is being investigated as a topical 0.05% gel rather than a systemic hormone-modifying treatment. However, the fact that its mechanism differs does not establish that it will produce greater hair density, faster responses or fewer adverse effects than approved treatments.
There are also unresolved questions about the persistence of regrowth after treatment stops. The Phase 2a study reported an early response after a short treatment course, but its follow-up was not long enough to establish durable benefit over years. Hair follicles undergo repeated cycles, and maintaining an improved growth pattern may require continued or intermittent treatment.
No completed head-to-head clinical trial has demonstrated that PP405 is superior to minoxidil or finasteride. Its competitive position will depend on AWAKEN’s results, longer-term tolerability, practical dosing requirements and whether the degree of visible improvement is meaningful to patients.
Why is Pelage initially testing men with Norwood-Hamilton Type IV and V hair loss?
The AWAKEN population has been selected to include men with a defined degree of established pattern hair loss. Norwood-Hamilton Type IV and V classifications generally indicate substantial thinning or hair loss involving characteristic frontal and crown regions. Selecting a relatively consistent severity range can help reduce variation when measuring treatment effects.
Patients with advanced hair loss may also present a particularly relevant test of PP405’s proposed ability to reactivate dormant follicles. A treatment that produces only modest changes in already-active follicles might have limited impact in visibly thinned areas. Demonstrating an increase in substantive hair count within such regions could provide evidence supporting the intended mechanism.
However, severity classifications do not directly establish how many dormant but viable follicles remain. Different individuals may have varying degrees of miniaturization, follicle damage and biological capacity for regrowth despite appearing to have similar hair-loss patterns. These differences can influence treatment response.
The trial’s age range of 18 to 55 also creates a defined development population. Results from these participants would not automatically establish effectiveness in older adults or younger adolescents. The company would need appropriate evidence before seeking a wider age indication.
AWAKEN’s quantitative hair-count endpoint and patient-reported outcomes may help clarify whether biological regrowth corresponds with improvements that patients actually notice. A statistically significant increase in follicle count is valuable, but the visible extent and perceived importance of the change will also matter.
What is Pelage planning for women with androgenetic alopecia?
Pelage expects to begin a separate Phase 2 trial involving women with androgenetic alopecia before the end of 2026. The earlier Phase 2a investigation included women as well as men, providing an initial basis for broader development. However, AWAKEN itself is specifically designed for male participants.
Female pattern hair loss can differ from male pattern hair loss in the distribution of thinning, hormonal influences and clinical presentation. Many affected women experience diffuse reduction in scalp hair density rather than the characteristic frontal recession seen in some men. These differences create a rationale for studying the populations separately.
The company’s non-hormonal mechanism may be relevant because treatment choices for women can be constrained by reproductive considerations and the indications of existing medicines. However, non-hormonal action should not be confused with established reproductive safety. Any investigational product intended for women requires appropriate evaluation according to the population being studied.
Pelage has not announced the complete protocol, enrollment target or primary endpoint for the proposed women’s Phase 2 investigation. Nor has it disclosed successful results from that future study. The programme therefore remains a planned expansion rather than an already completed clinical milestone.
The company hopes that targeting a shared biological feature of hair follicles will support treatment across sexes and potentially different forms of hair loss. That ambition remains dependent on clinical evidence in each proposed population.
How does the $120 million financing support late-stage PP405 development?
Pelage completed a $120 million Series B financing in October 2025, co-led by ARCH Venture Partners and GV, formerly Google Ventures. Existing investors including Main Street Advisors, Visionary Ventures and YK Bioventures also participated. The financing was intended to support clinical expansion and organizational growth as PP405 progressed toward late-stage trials.
Conducting a 600-patient multinational study creates materially greater operational demands than a 78-participant Phase 2a trial. The company must coordinate clinical sites, standardized photographic and hair-count assessments, treatment supply, safety monitoring and statistical analysis. Maintaining consistency across locations will be essential for interpreting the primary outcome.
The financing provides a foundation for those activities, although the company has not disclosed its current cash balance or a full budget for the AWAKEN programme. The previously announced $120 million should not be treated as a current unrestricted cash balance. Additional trials, including the planned programme in women, may also increase expenditure.
Pelage remains privately held and has not disclosed product revenue from PP405. The medicine is investigational and cannot yet be commercially marketed for androgenetic alopecia. Its future financial value will depend primarily on whether the larger clinical programme supports an approvable and commercially competitive treatment.
The transition into Phase 2/3 development therefore marks both scientific progress and a major increase in the evidence required from the company.
What must AWAKEN demonstrate before PP405 can reach patients?
The principal requirement is a convincing difference in non-vellus target area hair count between PP405 and vehicle at Week 24. The trial must establish not only statistical significance but also whether the magnitude of regrowth produces an improvement relevant to patients. Consistency across treatment centers and subgroups will help determine how broadly the findings may apply.
Long-term safety will be equally important. The short Phase 2a study reported favorable tolerability and no detectable systemic drug exposure under its testing conditions, but it cannot exclude uncommon adverse reactions or effects emerging with extended treatment. The 52-week AWAKEN design will provide additional information about repeated application.
Investigators will also need to understand the durability of regrowth and whether patients require ongoing treatment to maintain benefits. Hair-count measurements, patient-reported outcomes and other follicular assessments may help establish that relationship. However, the October first-patient announcement does not provide results from AWAKEN.
Pelage has initiated a substantial controlled trial aimed at validating a different approach to androgenetic alopecia. The early clinical evidence suggests that follicular metabolic activation may stimulate new hair growth in some patients, but the most widely discussed response percentage comes from a selected exploratory subgroup. The larger AWAKEN study will determine whether that finding represents a reproducible treatment effect with acceptable long-term safety.
If the programme succeeds, PP405 could add a non-hormonal therapeutic option to a field dominated by medicines acting through different mechanisms. Until the controlled results are available and regulators complete their review, the treatment remains investigational, with its clinical benefit and commercial potential still to be established.
